- Titre
- Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
- Créateurs - sans rôle
- Christoph Kornauth - Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaCharles Herbaux - Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, BostonBernd Boidol - Austrian Academy of SciencesChantal Guillemette - Centre Hospitalier Universitaire de Québec - Université Laval and Faculty of Pharmacy, Université Laval, QuébecPatrick Caron - Centre Hospitalier Universitaire de Québec - Université Laval and Faculty of Pharmacy, Université Laval, QuébecMarius E Mayerhöfer - Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, ViennaStéphanie Poulain - UMR CANTHER, INSERM 1277-CNRS 9020 UMRS 12. University of Lille, Hematology Laboratory, Biology and pathology center, CHU de Lille, 59000 LilleOlivier Tournilhac - Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite Clermont Auvergne, EA7453 CHELTER, CIC1405, Clermont FerrandTea Pemovska - Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaStephen J F Chong - Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, BostonEmiel Van der Kouwe - Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaLukas Kazianka - Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaGeorg Hopfinger - 3rd Medical Department, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, ViennaDaniel Heintel - 1. Medical Department, Center for Oncology and Hematology, Wilhelminenhospital Vienna, ViennaRoland Jäger - Department of Laboratory Medicine, Medical University of ViennaMarkus Raderer - Department of Medicine I, Division of Oncology, Medical University of ViennaUlrich Jäger - Medical University of ViennaIngrid Simonitsch-Klupp - Clinical Department of Pathology, Medical University of ViennaWolfgang R Sperr - Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of ViennaStefan Kubicek - Austrian Academy of SciencesMatthew S Davids - Harvard Medical SchoolPhilipp B Staber - Medical University of Vienna
- Détails de publication
- Haematologica (Roma), Vol.106(8), pp.2251-2256
- Note de subvention
- P 27132 / Austrian Science Fund FWF I 4154 / Austrian Science Fund FWF I 4156 / Austrian Science Fund FWF
- Identifiants
- 99139749709311
- Unité académique
- Institut de Génétique Humaine - IGH
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
Haematologica (Roma), Vol.106(8), pp.2251-2256
01/08/2021
PMID: 33626863
Indicateurs
1 Consultations de la notice